HOUSTON, April 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the receipt of newly issued patents in Mexico, Australia and Japan, and updated investors on the extent of its global intellectual property portfolio. Bio-Path has expanded its intellectual property portfolio by filing patent applications that ...

HOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides a clinical development and operational update for 2024. "The new year is off to a strong start as we build off positive data generated in 2023 that compel us to advance these studies as quickly as possible and to file for regulatory designations ...

Bio-Path Holdings Inc. (NASDAQ:BPTH) Q4 2023 Results Conference Call March 8, 2024 8:30 AM ET Company Participants Will O’Connor - Stern Investor Relations Peter Nielsen - CEO and CFO Anthony Price - SVP, Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - Roth MKM Operator Good morning, ladies and gentlemen, and welcome to the Bio-Path Holdings Full Year 2023 Earnings Conference Call. [Operator Instructions] Please also note today’s event is being recorded. At this time, ...

HOUSTON, March 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the year ended December 31, 2023 and provided an update on recent corporate developments. "2023 was a year of focused execution, as evidenced by the continued progress across our pipeline of DNAbilize programs," said P ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Common Stock, par value $0.001 per share BPTH The Nasdaq Capital Market Date of report (Date of earliest event reported): March 8, 2024 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401 (Address of principal executive offices) (Zip Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Indicate by check mark w ...

We have expanded our intellectual property portfolio by filing patent applications that are applicable to our technology and business strategy. Our patent portfolio currently includes five issued patents in the U.S. and 17 issued patents in foreign jurisdictions: | --- | --- | --- | |--------------------------|------------------------------------------------------------|-----------------------| | Patent No. | Title | Date Issued | | US 9,744,187 | P-ethoxy nucleic acids for liposomal formulation | August 29 ...

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2023 Earnings Call Transcript November 15, 2023 8:30 AM ET Company Participants Will O'Connor - IR, Stern IR Peter Nielsen - President and CEO Anthony Price - SVP of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Foll ...

Company History and Available Information For the transition period from __________ to __________ CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Research and development expenses consist of costs associated with our research activities, including the development of our drug candidates. Our research and development expenses consist of: Revenue. We had no revenue for each of the three months ended September 30, 2023 and 2022. Delaware 87-0652870 (State or other jurisdiction of (I.R.S. Employer incorpora ...

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants Will O'Connor - Investor Relations, Stern IR Peter Nielsen - President and Chief Executive Officer Anthony Price - Senior Vice President of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings Second Quarter 2023 Earnings Conference Call. [Operator Instructions] I would no ...

UNITED STATES FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) Table of Contents Washington, D.C. 20549 Or Commission file number: 001-36333 | --- | --- | |------------------------------------------------------------------------------|------------------------------------------| | Delaware | 87-0652870 | | (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification N ...